No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
SISRAM MED (01696.HK): Direct sales channels have significantly increased their share, and the launch of new injectable fillers is eagerly anticipated.
The company released the 2024 annual report, and the performance met expectations. 1) 2024 revenue of 0.349 billion USD (year-on-year -2.8%); Net income attributable to shareholders of 0.025 billion USD (year-on-year -20.2%). 2) 24H2 revenue of 1.8.
SISRAM MED (01696.HK): Innovation drives product line growth, direct sales strategy deepens Global collaboration and development.
Event: On March 19, 2025, the company announced its full-year performance for 2024, with revenue of 2.51 billion yuan, a year-on-year decrease of 2.8%; net income was 0.181 billion yuan, down year-on-year.
SISRAM MED (01696.HK): Direct sales proportion rises to 87%, pay attention to the approval milestones for botulinum toxin.
Event: SISRAM MED disclosed its annual performance for 2024: Annual revenue of 0.349 billion dollars (-2.8%), Net income of 0.025 billion dollars (-20.2%); for the second half of 2024.
Sisram Medical Posts Lower 2024 Profit
The annual net profit of SISRAM MED (01696.HK) is 25.13 million USD, down 20%. A final dividend of 12.6 Hong Kong cents is declared.
SISRAM MED (01696.HK) announced its financial results for the fiscal year 2024, with a revenue of 0.349 billion dollars, a year-on-year decrease of 2.8%. It recorded a net profit of 25.13 million dollars, down 20.2%, with earnings per share of 5.36 cents. The final dividend is 12.6 Hong Kong cents. In the same period last year, it was 15.8 Hong Kong cents.
SISRAM MED announces its full-year performance for 2024.
Leading the market with strategic resilience to promote regional breakthroughs and Global collaborative development. Hong Kong, March 19, 2025 /PR Newswire/ -- SISRAM MED Co., Ltd. (English "Sisram"; referred to as "the Company" or "SISRAM MED", stock code: 1696.HK, together with its subsidiaries referred to as "the Group"), today announced its audited consolidated annual results for the year ended December 31, 2024 ("the Reporting Period"). SISRAM MED is a Global beauty and health group, and its unique beauty and health ecosystem provides a diverse range of offerings centered on energy source devices and injection fillers.
